<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00537498</url>
  </required_header>
  <id_info>
    <org_study_id>MC-UK.2/AVK</org_study_id>
    <nct_id>NCT00537498</nct_id>
  </id_info>
  <brief_title>Urokinase Therapy in Diabetic Foot Syndrome</brief_title>
  <official_title>Phase II Study of Urokinase Therapy for Treatment of Angiopathic or Angioneuropathic Diabetic Foot Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>medac GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>medac GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether a treatment with urokinase (500 000 or 1 000
      000 IU) can lead to ulcer-healing, lower rate of major amputation, and prolonged survival in
      patients with diabetic foot syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with diabetic foot ulceration and critical limb ischemia have a high risk of major
      amputation especially if limbs cannot be revascularized. Urokinase is effective in improving
      the microcirculation in critical limb ischemia by lowering fibrinogen and might improve
      outcomes. There are however no data on the efficacy and safety of urokinase treatment in
      terms of survival free of major amputation, ulcer healing and the rate of minor and major
      bleeding. Therefore this trial is conducted to investigate the effect of urokinase treatment
      on these parameters.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2002</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients being alive, having no major amputation and healed ulceration</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Each of overall survival, major amputation rate, survival free of major amputation rate, rate of ulcer healing, and safety</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Diabetic Foot</condition>
  <condition>Arterial Occlusive Disease</condition>
  <condition>Ischemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interventional group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Urokinase</intervention_name>
    <description>Daily intravenous application of urokinase over 30 minutes
Dosage:
If plasma fibrinogen is &gt; 2,5g/l application of 1 000 000 IU Urokinase If plasma fibrinogen is &lt; 2,5g/l application of 500 000 IU Urokinase If plasma fibrinogen is &lt; 1,6g/l treatment must be stopped and continued after rising up to &gt;2g/l</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  angiopathic or angioneuropathic diabetic foot lesions

          -  critical limb ischemia

          -  no surgical or interventional treatment option

        Exclusion Criteria:

          -  feasibility of vascular surgery or angioplasty

          -  prior treatment of the current ulceration with urokinase

          -  need for dialysis

          -  creatinine &gt; 180µmol/l

          -  any kind of cerebral event less than three months before inclusion into the study

          -  proliferative retinopathy (not remediated)

          -  uncontrolled hypertension

          -  hemorrhagic diathesis

          -  gastrointestinal bleeding

          -  need for oral anticoagulation

          -  mental disorders

          -  pregnancy

          -  participation in another study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sebastian M. Schellong, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Carl Gustav Carus TU Dresden UniversitätsGefäßcentrum</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus UniversitätsGefäßcentrum</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2007</study_first_submitted>
  <study_first_submitted_qc>September 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2007</study_first_posted>
  <last_update_submitted>March 24, 2010</last_update_submitted>
  <last_update_submitted_qc>March 24, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2010</last_update_posted>
  <keyword>urokinase, diabetes, wound healing, major amputation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

